Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability

Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability

BOULDER -- Inscripta , a gene-editing technology company, today announced MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in... Read More

Thursday December 20, 2018 0 comments Tags: Boulder, Inscripta, MAD7, Kevin Ness

Inscripta announces two major milestones

Inscripta announces two major milestones

BOULDER -- Inscripta , a gene-editing technology company, announced two significant milestones. First, the USPTO granted Inscripta its first patent covering systems using MAD7, the... Read More

Friday July 13, 2018 0 comments Tags: Boulder, Inscripta, Dr. Kevin Ness, Jon Moore, MAD7, MAD2